Neurofibromatosis 1 Clinical Trial
Official title:
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2 Dose-Response Study to Determine Safety and Effectiveness of Two Concentrations of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
This is a randomized, double-blind, vehicle-controlled, parallel group dose response study evaluating the safety and effectiveness of 2 concentrations of NFX-179 Gel in subjects with cutaneous neurofibromas. At Visit 1, the investigator will identify 10 Target cNFs that fulfil the enrollment criteria. The Target cNFs must be located on the subject's face, anterior trunk, or upper extremities. Two Target cNFs must be on the face and 8 must be on the anterior trunk or upper extremities. The study medication will be applied topically QD to the Target cNFs for 182days (26 weeks). During the duration of the study subjects will be evaluated for safety and efficacy.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT01362803 -
AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT00352599 -
Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1)
|
Phase 1 | |
| Completed |
NCT03531814 -
Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1(NF1) on Clinical Treatment Trials
|
N/A | |
| Completed |
NCT00846430 -
Medical Treatment of "High-Risk" Neurofibromas
|
Phase 2 | |
| Completed |
NCT03433183 -
SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
|
Phase 2 | |
| Recruiting |
NCT05331105 -
HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
|
Phase 2 | |
| Completed |
NCT03310996 -
Non-invasive Stimulation in Neurofibromatosis Type 1
|
N/A | |
| Recruiting |
NCT03406208 -
Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing
|
N/A | |
| Not yet recruiting |
NCT05849662 -
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04750928 -
Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06262113 -
A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1
|
N/A | |
| Active, not recruiting |
NCT04924608 -
Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
|
Phase 3 | |
| Recruiting |
NCT02544022 -
Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)
|
||
| Recruiting |
NCT04941027 -
Evaluating Genetic Modifiers of Cutaneous Neurofibromas in Adults With Neurofibromatosis Type 1
|
||
| Completed |
NCT02153931 -
Internet Support Group for Parents of a Child With Neurofibromatosis Type 1
|
||
| Completed |
NCT05196854 -
Clinical Hypnosis and Home Blood Pressure Monitoring in Children With Neurofibromatosis Type 1
|
N/A | |
| Active, not recruiting |
NCT01650142 -
Modifying Genes in Neurofibromatosis 1
|
N/A | |
| Completed |
NCT05377008 -
Intervention Effectiveness on the Neurocognitive Functioning of Children and Adolescents With Neurofibromatosis Type 1
|
N/A | |
| Completed |
NCT04879160 -
Systematically Assessing Changes in Plexiform Neurofibroma Related Disfigurement From Photographs of Subjects With Neurofibromatosis Type 1 on a Phase 2 Clinical Trial
|
||
| Recruiting |
NCT05735717 -
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
|
Phase 2 |